Scilex Holding Company (SCLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scilex Holding Company (SCLX) has a cash flow conversion efficiency ratio of 0.004x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.11 Million) by net assets ($-254.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Scilex Holding Company (SCLX) net asset quality to measure how much of total assets are equity-financed.
Scilex Holding Company - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Scilex Holding Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Scilex Holding Company cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Scilex Holding Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scilex Holding Company ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PENTIXAPHARM HOLDING N AG
XETRA:PTP
|
N/A |
|
Talphera Inc.
NASDAQ:TLPH
|
-0.143x |
|
Regal Holding Co Ltd
TW:4807
|
-0.239x |
|
Ralco Agencies Ltd
TA:RLCO
|
0.141x |
|
Lion Chemtech Co. Ltd
KQ:171120
|
-0.035x |
|
Caprice Resources Limited
F:C3F
|
-0.006x |
|
Arrow Syndicate Public Company Limited
BK:ARROW
|
0.052x |
|
Ozderici Gayrimenkul Yatirim Ortakligi AS
IS:OZGYO
|
0.006x |
Annual Cash Flow Conversion Efficiency for Scilex Holding Company (2020–2025)
The table below shows the annual cash flow conversion efficiency of Scilex Holding Company from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Scilex Holding Company (SCLX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-211.75 Million | $3.82 Million | -0.018x | +82.06% |
| 2024-12-31 | $-192.64 Million | $19.35 Million | -0.100x | -183.88% |
| 2023-12-31 | $-172.94 Million | $-20.71 Million | 0.120x | +120.41% |
| 2022-12-31 | $36.24 Million | $-21.26 Million | -0.587x | -558.16% |
| 2021-12-31 | $-223.88 Million | $-28.66 Million | 0.128x | -42.34% |
| 2020-12-31 | $-141.68 Million | $-31.46 Million | 0.222x | -- |
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more